Hims & Hers Health (NYSE: HIMS), founded in 2017 by Andrew Dudum, is a US direct-to-consumer telehealth platform offering treatments for hair loss, sexual health, mental health, dermatology, and — most recently — weight loss (including compounded GLP-1 medications). The company went public via SPAC on January 21, 2021. The stock surged in 2024–2025 as GLP-1 demand exploded. If you had invested $1,000 in Hims at its IPO or 1 or 3 years ago, how much would you have today?
Consumers complete an online consultation with a licensed clinician, receive a prescription where clinically appropriate, and get ongoing recurring subscription fulfillment shipped to their door. This combines the convenience of D2C e-commerce, personalization of telemedicine, and the recurring revenue economics of a subscription business — with a distinctive lifestyle-brand aesthetic that resonates strongly with millennials and Gen Z.
Sexual health & hair loss (generic finasteride, minoxidil, ED treatments); mental health & dermatology (anxiety, depression, insomnia, personalized skincare); weight loss and GLP-1 (compounded semaglutide is the primary 2024–2025 growth catalyst); and a vertically integrated 503B outsourcing pharmacy facility enabling in-house compounding and fulfillment.
FDA declared semaglutide "no longer in shortage" in early 2025 — compounded GLP-1 sales face regulatory limits and legal challenges from Novo Nordisk and Eli Lilly; growth depends heavily on paid social and search, so rising CAC pressures margins; multi-state telehealth licensing, DEA rules on controlled prescriptions, and malpractice exposure are ongoing costs; and Ro, LifeMD, Amazon Pharmacy, and insurance-covered telehealth compete on price and breadth.
Custom-compounded personalized formulations across categories increase ARPU and reduce cross-shopping; a UK-launched brand and 2024 European entry via a licensing partner add a longer-term growth vector; and preventative and longevity care (blood tests, hormone optimization, longevity offerings) could dramatically expand TAM per user.
Hims is one of the fastest-growing consumer-health names of the 2020s, with genuine subscription economics and a differentiated brand. But the 2024–2025 GLP-1 boom drove much of the recent share-price surge and carries clear regulatory risk. Investors bullish on D2C healthcare as a durable model should size positions with volatility in mind.
Note: Hims does not pay a dividend, so total return is driven by price change. Excludes taxes, brokerage fees, and FX impact. HIMS stock is highly volatile — moves have been sharply amplified by GLP-1 news flow. Past performance is not a guarantee of future results. Data updates daily.